1. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Membrane Transporter/Ion Channel Neuronal Signaling Apoptosis
  2. COX Reactive Oxygen Species (ROS) Calcium Channel Ferroptosis Mitochondrial Metabolism MMP
  3. Diplacone

Diplacone  (Synonyms: Nymphaeol A; Propolin C)

Cat. No.: HY-N16129 Purity: 98.38%
Handling Instructions Technical Support

Diplacone is an orally active geranyl flavanone. It is isolated from the fruits of Paulownia tomentosa. Diplacone reduces COX-2 levels and increases the pro-MMP2/MMP2 ratio. It induces ferroptosis-mediated cell death. Diplacone enhances mitochondrial Ca2+ influx and ROS production. It possesses anti-inflammatory and free radical-scavenging activities. Diplacone can be used in research related to ulcerative colitis and non-small cell lung cancer.

For research use only. We do not sell to patients.

Diplacone

Diplacone Chemical Structure

CAS No. : 73676-38-7

Size Price Stock Quantity
1 mg In-stock
5 mg Get quote
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Diplacone is an orally active geranyl flavanone. It is isolated from the fruits of Paulownia tomentosa. Diplacone reduces COX-2 levels and increases the pro-MMP2/MMP2 ratio. It induces ferroptosis-mediated cell death. Diplacone enhances mitochondrial Ca2+ influx and ROS production. It possesses anti-inflammatory and free radical-scavenging activities. Diplacone can be used in research related to ulcerative colitis and non-small cell lung cancer[1][2][3].

IC50 & Target[1]

COX-2

 

MMP-2

 

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
5.5 μg/mL
Compound: 4
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
[PMID: 15787448]
A2780cisR IC50
10.5 μM
Compound: 10
Antiproliferative activity against drug-sensitive human A2780 cells
Antiproliferative activity against drug-sensitive human A2780 cells
[PMID: 17326683]
A549 IC50
4 μM
Compound: Nymphaeol A
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
[PMID: 28814374]
BC IC50
2.7 μg/mL
Compound: 4
Cytotoxicity against human BC cells
Cytotoxicity against human BC cells
[PMID: 15974621]
BJ EC50
5.9 μM
Compound: 8
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
CCRF-CEM EC50
3.2 μM
Compound: 8
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
HeLa EC50
< 10 μM
Compound: 8
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
KB IC50
4.6 μg/mL
Compound: 4
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 15974621]
MCF7 EC50
< 10 μM
Compound: 8
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
NCI-H187 IC50
1.5 μg/mL
Compound: 4
Cytotoxicity against human NCI-H187 cells
Cytotoxicity against human NCI-H187 cells
[PMID: 15974621]
RPMI-8226 EC50
< 10 μM
Compound: 8
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
THP-1 EC50
< 10 μM
Compound: 8
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
[PMID: 20192247]
THP-1 IC50
> 10 μM
Compound: 22
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
[PMID: 25735399]
U-266 EC50
2.4 μM
Compound: 8
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
[PMID: 20192247]
Vero IC50
3.8 μg/mL
Compound: 4
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
[PMID: 15974621]
In Vitro

Diplacone inhibits LPS-induced inflammatory responses and reduces the expression of COX-2 in mouse macrophages[1].
Diplacone (pre-incubated for 1 h before lipopolysaccharide stimulation at concentrations of 10-20 μM) downregulates the gene expression of LPS-induced pro-inflammatory factors TNF-α and MCP-1, and upregulates the expression of LPS-induced anti-inflammatory gene ZFP36. In macrophages differentiated from the THP-1 human monocytic leukemia cell line, it doubles the total production of TNF-α mRNA, halves the total production of MCP-1 mRNA, and slightly increases the total production of ZFP36 mRNA[2].
Diplacone (5-40 μM; 24-48 h) potently inhibits the viability of human non-small cell lung cancer A549 cells, with an IC50 value of 10.6 μM at 24 h and 7.9 μM at 48 h[3].
Diplacone (20-40 μM; 1 min) increases the cytoplasmic Ca2+ concentration in non-small cell lung cancer A549 cells[3].
Diplacone (20-40 μM; 3-24 h) induces loss of mitochondrial membrane potential in non-small cell lung cancer A549 cells[3].
Diplacone (40 μM; 3-24 h) induces time-dependent upregulation of ATF3 protein expression in non-small cell lung cancer A549 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR[2]

Cell Line: Differentiated THP-1 human monocytic leukaemia cell line-derived macrophages
Concentration: 10 μM; 20 μM
Incubation Time: 1 h (pre-incubation); 1, 2, 4, 6, 10, 24 h (post-LPS stimulation harvest)
Result: Significantly decreased TNF-α gene expression at 2 h post-LPS (P < 0.001) and significantly increased it at 4, 10, and 24 h post-LPS (P < 0.05) at 10 μM.
Significantly decreased TNF-α gene expression at 2 h post-LPS (P < 0.001), significantly decreased it at 1 h post-LPS (P < 0.05), and significantly increased it at 24 h post-LPS (P < 0.05) at 20 μM.
Significantly decreased MCP-1 gene expression at 4 h post-LPS (P < 0.0005), 6 h post-LPS (P < 0.0001), and 10 h post-LPS (P < 0.0001) at 10 μM.
Significantly decreased MCP-1 gene expression at 4 h post-LPS (P < 0.0001), 6 h post-LPS (P < 0.0001), and 10 h post-LPS (P < 0.0001) at 20 μM.

Cell Viability Assay[3]

Cell Line: A549 human non-small cell lung cancer cells
Concentration: 5-40 μM
Incubation Time: 24 h; 48 h
Result: Inhibited A549 cell viability in a dose-dependent manner.
Reached IC50 values of 10.6 μM (24 h) and 7.9 μM (48 h).

Western Blot Analysis[3]

Cell Line: A549 human non-small cell lung cancer cells
Concentration: 40 μM
Incubation Time: 3, 6, 9, 12, 24 h
Result: Increased ATF3 protein expression in a time-dependent manner, with relative expression levels of 2.75-fold (3 h), 3.58-fold (6 h), 2.87-fold (9 h), 2.9-fold (12 h), and 3.2-fold (24 h) compared to control.
In Vivo

Diplacone (25 mg/kg; i.g.; 48 h and 24 h pre-colitis induction, then every 24 h during DSS exposure) significantly reduces colitis severity in Wistar rats, achieving a statistically significant reduction in disease activity index, 55.9% lower COX-2 levels, and a 50.7% higher pro-MMP2/MMP2 ratio compared to untreated DSS-exposed rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (male, 180-220 g, ulcerative colitis induced by 10% DSS in drinking water for 5 days)[1]
Dosage: 25 mg/kg
Administration: i.g.; 48 h and 24 h pre-colitis induction, then every 24 h during DSS exposure
Result: Ameliorated colitis symptoms (diarrhea, rectal bleeding) and delayed symptom onset.
Showed the lowest disease activity index (DAI) on the final day of the experiment, with a statistically significant reduction compared to the DSS-only group (### p < 0.001).
Reduced colon weight/length ratio increase to 20.4% relative to the intact group.
Reduced colonic COX-2 levels by 55.9% compared to the DSS-only group.
Increased the pro-MMP2/MMP2 ratio by 50.7% compared to the DSS-only group.
Reduced colonic levels of antioxidant enzymes SOD2 and CAT.
Resulted in an 87.5% survival rate (1 of 8 rats died).
Molecular Weight

424.49

Formula

C25H28O6

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC1=C2C(O[C@H](C3=CC(O)=C(C=C3)O)CC2=O)=CC(O)=C1C/C=C(C)/CC/C=C(C)\C

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Diplacone
Cat. No.:
HY-N16129
Quantity:
MCE Japan Authorized Agent: